BUFFALO GROVE, Ill., Sept. 3, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.  

Mr. Simes' presentation at the Rodman & Renshaw Global Investment Conference is scheduled for September 9, 2015 at 4:15 pm ET in New York City. A live webcast of the presentation will be available at http://wsw.com/webcast/rrshq25/resx.  For those who are not available to listen to the live webcast, a replay will be archived at http://wsw.com/webcast/rrshq25/resx.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.

CONTACT: The Trout Group LLC
         Marcy Nanus, 646-378-2927
         mnanus@troutgroup.com
         
         PCG Advisory Group
         Stephanie Prince, 646-762-4518
         sprince@pcgadvisory.com